Trial Profile
LP0058-1005 - A Phase I, Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects When Administered as an Immediate and Modified Release Formulation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Mar 2015
Price :
$35
*
At a glance
- Drugs Orismilast (Primary)
- Indications Psoriasis
- Focus Pharmacokinetics
- Sponsors LEO Pharma
- 10 Mar 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Jan 2015 According to ClinicalTrial.gov record, planned End Date changed from 1 Jul 2014 to 1 Jan 2015.
- 21 Jan 2015 According to ClinicalTrial.gov record, planned primary completion date changed from 1 Jul 2014 to 1 Jan 2015.